Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems DAEJEON, South Korea, June 20, 2024 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, announced the signing of a strategic Memorandum...

Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the BIO International Convention...

Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the 20th Annual PEGS Boston –...

Syntekabio to Showcase Innovative AI Drug Discovery Technologies at Bio-IT World NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the upcoming Bio-IT World...

Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22 New York, N.Y., United States, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology...